Regulation of hematopoietic stem cell processing and transplantation

International Journal of Hematology

Volumn 75, Issue 3, 2002, Pages 237-245

  Rowley, Scott D ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplantation; Current good manufacturing practices (cGMP); Current good tissue practices (cGTP); Hematopoietic stem cell (HSC) transplantation; Regulation; The Food and Drug Administration (FDA)

Indexed keywords

ACCREDITATION; ADOPTIVE IMMUNOTHERAPY; ARTICLE; DONOR SELECTION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; QUALITY CONTROL; BONE MARROW TRANSPLANTATION; HEALTH CARE QUALITY; HEMATOPOIETIC STEM CELL; PHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; STANDARD; UNITED STATES;

ACCREDITATION; BONE MARROW TRANSPLANTATION; GUIDELINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036547470     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982036     Document Type: Article

References (24)

1. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
2. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Ann Rev Med. 1999;50:507-529.
3. Pecora AL. Progress in clinical application of use of progenitor cells expanded with hematopoietic growth factors. Curr Opin Hematol. 2001;8:142-148.
4. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;2:1549-1555.
5. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815-1822.
6. Human tissue intended for transplantation, 58 Federal Register 65514 (1993).
7. Human Tissue Intended for Transplantation, 62 Federal Register 40429 (1997).
8. A proposed approach to the regulation of cellular and tissue-based products, 62 Federal Register 9721 (1997).
9. Kessler DA, Siegel JP, Noguchi PD, et al. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N Engl J Med. 1993;329:1169-1173.
10. Application of current statutory authorities to human somatic cell therapy products and gene therapy products, 58 Federal Register 53248 (1993).
11. Draft document concerning the regulation of placental/umbilical cord blood stem cell products intended for transplantation or further manufacture into injectable products, [availability], 61 Federal Register 7087 (1996).
12. Food and Drug Administration. Guidance for Human Somatic Cell Therapy and Gene Therapy. Rockville, Md: National Press Office: March, 1998.
13. Human cells, tissues, and cellular and tissue-based products; establishment registration and listing [final rule], 66 Federal Register 5447 (2001).
14. CFR 600.11(e)(3), 1998.
15. CFR 600.11(e)(4), 1998.
16. Food and Drug Administration. Guidance for the submission of chemistry, manufacturing, and controls information and establishment description for autologous somatic cell therapy products. Docket 95N-0200: Part 2.B.2. (1997).
17. Food and Drug Administration. Guidance for the submission of chemistry, manufacturing, and controls information and establishment description for autologous somatic cell therapy products. Docket 95N-0200: Part 2.B.3. (1997).
18. CFR 211.28(d), 1998.
19. CFR 600.10(c)(4), 1998.
20. CFR 211.84(b), 1998.
21. CFR 211.100(b), 1998.
22. The Food and Drug Administration's development, issuance, and use of guidance documents. 62 Federal Register 8961 (1997).
23. Standards for Hematopoietic Progenitor Cell Collection, Processing & Transplantation, First Edition. Omaha, Neb: Foundation for the Accreditation of Hematopoietic Cell Therapy; 1996.
24. Request for proposed standards for unrelated allogeneic peripheral and placental/umbilical cord blood hematopoietic stem/progenitor cell products; request for comments. 63 Federal Register 2985 (1998).